DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorder	Recruiting	Phase 2 / Phase 3	2024-04-03		NCT06221748

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
RemeGen Co., Ltd.	36

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Cancer Hospital	Beijing	China	208
Harbin Medical University Cancer Hospital	Harbin	China	102
Hubei Cancer Hospital	Wuhan	China	95
Hunan Cancer Hospital	Changsha	China	27
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	China	27
Shandong Cancer Hospital	Jinan	China	86
The Affiliated Hospital of Qingdao University	Qingdao	China	27
The First Affiliated hospital of Xiamen University	Xiamen	China	69
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	125
West China Hospital of Sichuan University	Chengdu	China	117
Xuzhou Central Hospital	Xuzhou	China	20
Yunnan Cancer Hospital	Kunming	China	44